krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)
Company profile
Ticker
KRYS
Exchange
Website
CEO
Krish S. Krishnan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
–Krystal Biotech Switzerland GmbH ...
KRYS stock data
Latest filings (excl ownership)
8-K
Krystal Biotech Announces Fourth Quarter and Full Year 2023
26 Feb 24
S-8
Registration of securities for employees
26 Feb 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
6 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Departure of Directors or Certain Officers
7 Aug 23
8-K
Krystal Biotech Announces Second Quarter 2023 Financial Results and
7 Aug 23
10-Q
2023 Q1
Quarterly report
7 Aug 23
8-K
Krystal Biotech Announces Pipeline Expansion into Oncology
26 Jul 23
S-3ASR
Automatic shelf registration
18 Jul 23
Latest ownership filings
4
Suma Krishnan
11 Mar 24
4
Krish S Krishnan
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
KATHRYN ROMANO
1 Mar 24
4
KATHRYN ROMANO
1 Mar 24
4
Suma Krishnan
1 Mar 24
4
Krish S Krishnan
1 Mar 24
4
Suma Krishnan
28 Feb 24
4
Krish S Krishnan
28 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 373.24 mm | 373.24 mm | 373.24 mm | 373.24 mm | 373.24 mm | 373.24 mm |
Cash burn (monthly) | (no burn) | (no burn) | 8.66 mm | 12.30 mm | 7.08 mm | 8.66 mm |
Cash used (since last report) | n/a | n/a | 51.89 mm | 73.68 mm | 42.37 mm | 51.85 mm |
Cash remaining | n/a | n/a | 321.35 mm | 299.56 mm | 330.87 mm | 321.39 mm |
Runway (months of cash) | n/a | n/a | 37.1 | 24.3 | 46.8 | 37.1 |
Institutional ownership, Q3 2023
90.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 189 |
Opened positions | 19 |
Closed positions | 18 |
Increased positions | 89 |
Reduced positions | 52 |
13F shares | Current |
---|---|
Total value | 2.71 tn |
Total shares | 25.58 mm |
Total puts | 181.05 k |
Total calls | 162.10 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
FMR | 2.63 mm | $305.01 bn |
Avoro Capital Advisors | 2.57 mm | $297.60 bn |
Vanguard | 2.40 mm | $278.42 bn |
Redmile | 2.00 mm | $232.39 bn |
BLK Blackrock | 1.70 mm | $197.46 bn |
STT State Street | 1.03 mm | $119.69 bn |
Frazier Life Sciences Management | 988.46 k | $114.66 bn |
Sun Pharma | 914.11 k | $78.12 mm |
Frazier Life Sciences IX | 895.00 k | $53.70 mm |
Point72 Asset Management | 698.16 k | $80.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | Yes | Yes | 174.1313 | 800 | 139.31 k | 1,550,882 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | Yes | Yes | 173.2991 | 3,587 | 621.62 k | 1,551,682 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | Yes | Yes | 172.2057 | 2,800 | 482.18 k | 1,555,269 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | Yes | Yes | 171.0939 | 5,469 | 935.71 k | 1,558,069 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | Yes | Yes | 170.4196 | 8,040 | 1.37 mm | 1,563,538 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | Yes | Yes | 168.9574 | 1,646 | 278.10 k | 1,571,578 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | Yes | Yes | 168.1508 | 2,658 | 446.94 k | 1,573,224 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | No | Yes | 173.9959 | 1,314 | 228.63 k | 1,612,262 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | No | Yes | 173.0879 | 3,359 | 581.40 k | 1,613,576 |
11 Mar 24 | Krish S Krishnan | Common Stock | Sell | Dispose S | No | Yes | 172.0593 | 2,816 | 484.52 k | 1,616,935 |
News
(KRYS) - Analyzing Krystal Biotech's Short Interest
13 Mar 24
$100 Invested In This Stock 5 Years Ago Would Be Worth $800 Today
12 Mar 24
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
5 Mar 24
$1000 Invested In This Stock 5 Years Ago Would Be Worth $7,400 Today
29 Feb 24
Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results
27 Feb 24
Press releases
Thinking about buying stock in GameStop, Equinix, Lyra Therapeutics, Krystal Biotech, or KULR Technology?
26 Mar 24
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
28 Feb 24
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
8 Feb 24